中国经济网北京4月5日讯上海证券交易所上市审核委员会2025年第11次审议会议于2025年4月3日召开， 审议结果显示，技源集团股份有限公司(以下简称"技源集团")首发符合发行条件、上市条件和信息披露 要求。这是今年过会的第9家企业(其中，上交所和深交所一共过会8家，北交所过会1家)。 技源集团的保荐机构(主承销商)为东方证券股份有限公司，保荐代表人为王国胜、曹明。这是东方证券 今年保荐成功的第1单IPO项目。 技源集团是一家专业从事膳食营养补充产品研发创新及产业化的国际化企业集团。 截至招股说明书签署日，技源(香港)有限公司(以下简称"技源香港")持有技源集团股份数量为27,567.38 万股，占技源集团总股本的比例为78.76%，系技源集团控股股东。 截至招股说明书签署日，周京石、龙玲夫妇持有TSI Group Limited(以下简称"TSI Group")58.91%股权、 TSI Holdings International Inc.(以下简称"TSI Holdings")62.82%股权，TSI Group和TSI Holdings分别持有 技源香港90.91%和9.09%股权；同时龙玲持有江阴技 ...

Core Viewpoint - The Shanghai Stock Exchange has approved the IPO of Jiyuan Group, a company specializing in the research and development of dietary nutritional supplements, marking a significant step in its growth and expansion in the global market [1]. Company Overview - Jiyuan Group is an international enterprise focused on the R&D and industrialization of dietary nutritional supplements, providing innovative and customized nutritional raw materials and formulations [2]. - The company is the largest global supplier of HMB (beta-hydroxy-beta-methylbutyrate) and a core supplier of high-quality glucosamine and other products, with a strong market presence across major regions including China, Asia, the US, Europe, Australia, and South America [2][9]. Financial Performance - The company reported revenues of 947 million yuan, 892 million yuan, and 1.002 billion yuan for the years 2022, 2023, and 2024, respectively, with net profits of 143 million yuan, 153 million yuan, and 171 million yuan during the same period [4]. - As of December 31, 2024, total assets amounted to 1.186 billion yuan, with a debt-to-asset ratio of 20.23% [5]. - The company anticipates a revenue growth of approximately 14.39% year-on-year for Q1 2025, with net profit expected to increase by about 6.42% to 11.55% [5]. Market Position - Jiyuan Group holds a market share of approximately 65.80% in the global HMB market, with projected shares of 52.27% and 53.34% for 2023 and 2024, respectively [9]. - The company has established a solid position in the glucosamine market, with market shares of 11.92%, 13.85%, and 12.61% from 2022 to 2024 [10]. Client Relationships - The company heavily relies on Abbott Group, with sales to Abbott accounting for 23.44%, 17.38%, and 19.44% of its main business revenue over the reporting periods, and 69.26%, 64.69%, and 66.19% of its HMB business revenue [11]. - Over 90% of the company's revenue comes from international sales, primarily in the US, Europe, Australia, and Southeast Asia [11]. IPO Fund Utilization - The company plans to raise 603 million yuan through its IPO, which will be allocated to the construction of a nutritional health raw material production base, expansion of production lines, establishment of a technology innovation center, and to supplement working capital [7][8].